“This suggests to us that ultimately, the ideal situation is to develop pathway-specific therapies that would allow us to optimize the treatment potential, and minimize the side effects,” Dr. Guo concluded. “In addition, mitochondrial dynamics may be a novel target for mitochondrial forms of Parkinson’s disease.”
—Laura Sassano